Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )

Carfilzomib and irinotecan in relapsed small cell lung cancer

Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA

Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )

FORTE trial results: KRd with or without transplantation in newly diagnosed...

Dr Francesca Gay - University Hospital City of Health and Science of Turin...

FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status ( Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turin, Italy )

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...

Dr Zahi Mitri - OHSU Hospital, Portland, USA

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in...

Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA

ANNOUNCE: Combination of olaratumab and doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcomas ( Dr William Tap - Memorial Sloan Kettering Cancer Center, New York, USA )

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients...

Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC ( Dr Justin F. Gainor - Massachusetts General Hospital, Boston, USA )

ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

$ZUMA-3: A study of KTE-X19 in adults with relapsed/refractory acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )$

A severe lack of cancer care in Burundi

Dr Canesius Uwizeyimana - Radiation Oncology Medical Physicist, Bujumbura...

A severe lack of cancer care in Burundi ( Dr Canesius Uwizeyimana - Radiation Oncology Medical Physicist, Bujumbura, Burundi )

Better education about breast cancer treatment in Africa

Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International...

Better education about breast cancer treatment in Africa ( Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International, Accra, Ghana )

Improving radiotherapy access in Africa

Dow Wilson - CEO, Varian Medical Systems

Improving radiotherapy access in Africa ( Dow Wilson - CEO, Varian Medical Systems )

Improving communication and collaboration to tackle cancer in Africa

Prof Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA

Improving communication and collaboration to tackle cancer in Africa ( Prof Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer